Acrobiosystems for English
icon_bulk_orderConsulta masiva/Pedido rápido
user
  1. Cuadro de mandos
  2. Mi perfil
  3. Mi dirección
  4. Mis pedidos
  5. Afiliación a Acro
Iniciar sesión Registro
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
No hay productos en el carro de la compra
Mi carro|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Fc gamma RIII / CD16

Fc gamma RIII / CD16

Brief Information

Name:Low affinity immunoglobulin gamma Fc region receptor III-A
Target Synonym:Fc Fragment Of IgG, Low Affinity IIIa, Receptor (CD16a),CD16a Antigen,IGFR3,FCG3,Fc Fragment Of IgG, Low Affinity IIIa, Receptor For (CD16),Fc Fragment Of IgG, Low Affinity III, Receptor For (CD16),Immunoglobulin G Fc Receptor III,Fc-Gamma Receptor III-2 (CD 16),Neutrophil-Specific Antigen NA,Fc-Gamma Receptor IIIb (CD16),Fc Gamma Receptor III-A,Fc Gamma Receptor IIIa,Fc-Gamma RIIIa,Fc-Gamma RIII,FCGRIII,FcRIIIa,FCR-10,FCRIII,IMD20,CD16,Low affinity immunoglobulin gamma Fc region receptor III-A,
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Product> Filter Results
Por estado del producto :
Por categoría de producto :
Por especies :
Por etiqueta :
Por Conjugado::
Cat. No. Especies Descripción del producto Estructura Pureza Característica
FC6-M82E0 Mouse Biotinylated Mouse Fc gamma RIII / CD16 Protein, His,Avitag™ (MALS & SPR verified)
FC6-M82E0-structure
FC6-M82E0-sds
FC6-R52H6 Rhesus macaque Rhesus macaque Fc gamma RIII / CD16 Protein, His Tag (SPR & BLI & MALS verified)
FC6-R52H6-structure
FC6-R52H6-sds
FC6-C82E0 Cynomolgus Biotinylated Cynomolgus Fc gamma RIII / CD16 Protein, His,Avitag™ (MALS & BLI verified)
FC6-C82E0-structure
FC6-C82E0-sds
FC6-C52H9 Cynomolgus Cynomolgus Fc gamma RIII / CD16 Protein, His Tag (MALS & BLI verified)
FC6-C52H9-structure
FC6-C52H9-sds
CDA-M52H8 Mouse Mouse Fc gamma RIII / CD16 Protein, His Tag (SPR & BLI & MALS verified)
CDA-M52H8-structure
CDA-M52H8-sds
ACRO Quality

Part of Bioactivity data

FC6-M82E0-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Mouse CD16, His,Avitag (Cat. No. FC6-M82E0) captured on Biotin CAP- Series S Sensor Chip can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3) with an affinity constant of 0.345 μM as determined in a SPR assay (Biacore T200) (QC tested).

Protocol
FC6-R52H6-SPR
Human_FcRn_Heterodimer_Protein_SPR

Rhesus macaque CD16, His Tag (Cat. No. FC6-R52H6) captured on CM5 Chip via anti-His antibody can bind Rituximab with an affinity constant of 0.232 μM as determined in SPR assay (Biacore T200) (QC tested).

Protocol

Synonym Name

FCGR3

Background

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed  natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Acimtamig AFM-13 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides Details
AFM-24 AFM-24 Phase 2 Clinical Affimed Solid tumours Details
IPH-6501 IPH-6501; IPH-65 Phase 2 Clinical Innate Pharma SA Neoplasms; Lymphoma, Non-Hodgkin Details
SAR445514 SAR445514; SAR-445514; IPH6401/SAR514 Phase 2 Clinical Sanofi Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma Details
SAR-443579 SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 Phase 2 Clinical Sanofi Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute Details
FT-538 FT-538 Phase 2 Clinical Fate Therapeutics Inc Leukemia, Myeloid; Ovarian Neoplasms; Solid tumours; HIV Infections; Coronavirus Disease 2019 (COVID-19); Neoplasms; Respiratory Distress Syndrome, Adult; Peritoneal Neoplasms; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms Details
GMA-161 GMA-161 Phase 1 Clinical Sanofi, Macrogenics Inc Purpura, Thrombocytopenic, Idiopathic Details
FT-576 FT-576 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Bone Marrow Neoplasms; Multiple Myeloma Details
AFM-28 AFM-28 Phase 1 Clinical Affimed Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute Details
SM-3321 SM-3321; SM3321 Phase 1 Clinical Beijing StarMab BioMed Technology Ltd Solid tumours; Neoplasms; Leukemia, Myeloid, Acute Details
FT-596 FT-596 Phase 1 Clinical Fate Therapeutics Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
FT-516 FT-516 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms Details
Acimtamig AFM-13 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides Details
AFM-24 AFM-24 Phase 2 Clinical Affimed Solid tumours Details
IPH-6501 IPH-6501; IPH-65 Phase 2 Clinical Innate Pharma SA Neoplasms; Lymphoma, Non-Hodgkin Details
SAR445514 SAR445514; SAR-445514; IPH6401/SAR514 Phase 2 Clinical Sanofi Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma Details
SAR-443579 SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 Phase 2 Clinical Sanofi Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute Details
FT-538 FT-538 Phase 2 Clinical Fate Therapeutics Inc Leukemia, Myeloid; Ovarian Neoplasms; Solid tumours; HIV Infections; Coronavirus Disease 2019 (COVID-19); Neoplasms; Respiratory Distress Syndrome, Adult; Peritoneal Neoplasms; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms Details
GMA-161 GMA-161 Phase 1 Clinical Sanofi, Macrogenics Inc Purpura, Thrombocytopenic, Idiopathic Details
FT-576 FT-576 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Bone Marrow Neoplasms; Multiple Myeloma Details
AFM-28 AFM-28 Phase 1 Clinical Affimed Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute Details
SM-3321 SM-3321; SM3321 Phase 1 Clinical Beijing StarMab BioMed Technology Ltd Solid tumours; Neoplasms; Leukemia, Myeloid, Acute Details
FT-596 FT-596 Phase 1 Clinical Fate Therapeutics Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
FT-516 FT-516 Phase 1 Clinical University Of Minnesota, Fate Therapeutics Inc Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
Correo electrónico
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Dejar un mensaje

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap